Marstacimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Marstacimab. Educational only — not medical advice.
Labeled uses
HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.
Source: FDA labeling via NIH DailyMed (set a2cc631e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.